<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972320</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1601</org_study_id>
    <nct_id>NCT02972320</nct_id>
  </id_info>
  <brief_title>Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic</brief_title>
  <official_title>Lobaplatin Combined With Etoposide for First-line Treatment in Extensive Stage Sclc Then Benefit Patients Follow up Temozolomide Maintain Therapeutic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yunpeng Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates temozolomide maintain therapeutic efficacy and safety in extensive stage
      SCLC who has clinical benefit from etoposide combined Los platinum (EL) scheme in the first
      line treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the etoposide combined Los platinum (EL) plan administration, every cycle was 21
      days, a total of four cycle. The patients who was clinical benefit directly from EL scheme in
      the first line treatment accept temozolomide maintenance therapy, 150mg / m2, oral D1-5. A
      period of 28 days, regular follow-up and evaluation of effectiveness, safety and quality of
      life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival in the first line of chemotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>The first day of treatment to the date that disease progression is reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>The first day of treatment to death or last survival confirm date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Rate (RR)</measure>
    <time_frame>3 months</time_frame>
    <description>The ratio between the number of responders and number of patients assessable for tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>the first date of treatment to 30 days after the last dose of study drug, assessed up to 6 months</time_frame>
    <description>Treatment-related adverse events are assessed by common terminology criteria for adverse events (CTCAE) V4.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Extensive Stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>temozolomide maintain therapeutic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>temozolomide maintain therapeutic</description>
    <arm_group_label>temozolomide maintain therapeutic</arm_group_label>
    <other_name>Temozolomide Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 18 to 70 years old, men and women are not limited;

          2. confirmed by histopathological examination SCLC;

          3. clinical stage for patients with extensive stage (except for the case of pleural
             effusion)

          4. patients has no drug treatment history

          5. the implementation of palliative radiotherapy for metastatic lesions, surgical
             treatment, after the end of treatment over 14 days.

          6. there can be measured lesions (non radiation exposure site) of patients (RECIST)
             evaluation;

          7. physical condition score ECOG PS:0-1

          8. more than expected survival time over 3 months

        Exclusion Criteria:

          1. the previous platinum compounds have a history of allergies;

          2. active ulcer patients;

          3. Patients with primary lung lesions were treated with radiotherapy;

          4. chest X-ray showed clear interstitial pneumonia or patients with pulmonary fibrosis;

          5. the need for treatment of brain metastases in the active phase

          6. there are more serious tumor invasion, superior vena cava syndrome, or in the middle
             volume of malignant pleural effusion, abdominal effusion or pericardial effusion, not
             yet control;

          7. there is a serious infection, ADH abnormal secretion syndrome, poor control of
             diabetes,the need for the treatment of patients with severe complications such as vena
             cava syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>mingfang zhao, professor</last_name>
    <phone>13644055129</phone>
    <email>zhaomf618@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mingfang zhao, professor</last_name>
      <phone>13644055129</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director, clinical research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

